• 

  Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. 

  Khan, AA; Paget, JT; McLaughlin, M; Kyula, JN; Wilkinson, MJ; Pencavel, T; Mansfield, D; Roulstone, V; Seth, R; Halle, M; Somaiah, N; Boult, JKR; Robinson, SP; Pandha, HS; Vile, RG; Melcher, AA; Harris, PA; Harrington, KJ (2018-01-24)

  Improvements in cancer survival mean that long-term toxicities, which contribute to the morbidity of cancer survivorship, are being increasingly recognized. Late adverse effects (LAEs) in normal tissues after radiotherapy ...
• 

  Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy. 

  Dean, J; Wong, K; Gay, H; Welsh, L; Jones, A-B; Schick, U; Oh, JH; Apte, A; Newbold, K; Bhide, S; Harrington, K; Deasy, J; Nutting, C; Gulliford, S (2018-01)

  Severe acute dysphagia commonly results from head and neck radiotherapy (RT). A model enabling prediction of severity of acute dysphagia for individual patients could guide clinical decision-making. Statistical associations ...
• 

  Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. 

  Samson, A; Scott, KJ; Taggart, D; West, EJ; Wilson, E; Nuovo, GJ; Thomson, S; Corns, R; Mathew, RK; Fuller, MJ; Kottke, TJ; Thompson, JM; Ilett, EJ; Cockle, JV; van Hille, P; Sivakumar, G; Polson, ES; Turnbull, SJ; Appleton, ES; Migneco, G; Rose, AS; Coffey, MC; Beirne, DA; Collinson, FJ; Ralph, C; Alan Anthoney, D; Twelves, CJ; Furness, AJ; Quezada, SA; Wurdak, H; Errington-Mais, F; Pandha, H; Harrington, KJ; Selby, PJ; Vile, RG; Griffin, SD; Stead, LF; Short, SC; Melcher, AA (2018-01-03)

  Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined ...
• 

  HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. 

  Martins, CD; Da Pieve, C; Burley, TA; Smith, R; Ciobota, DM; Allott, L; Harrington, KJ; Oyen, WJG; Smith, G; Kramer-Marek, G (2018-02-06)

  Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). ...
• 

  3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. 

  Iveson, TJ; Kerr, RS; Saunders, MP; Cassidy, J; Hollander, NH; Tabernero, J; Haydon, A; Glimelius, B; Harkin, A; Allan, K; McQueen, J; Scudder, C; Boyd, KA; Briggs, A; Waterston, A; Medley, L; Wilson, C; Ellis, R; Essapen, S; Dhadda, AS; Harrison, M; Falk, S; Raouf, S; Rees, C; Olesen, RK; Propper, D; Bridgewater, J; Azzabi, A; Farrugia, D; Webb, A; Cunningham, D; Hickish, T; Weaver, A; Gollins, S; Wasan, HS; Paul, J (2018-04)

  BACKGROUND: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior ...
• 

  Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. 

  Abubakar, M; Chang-Claude, J; Ali, HR; Chatterjee, N; Coulson, P; Daley, F; Blows, F; Benitez, J; Milne, RL; Brenner, H; Stegmaier, C; Mannermaa, A; Rudolph, A; Sinn, P; Couch, FJ; Devilee, P; Tollenaar, RAEM; Seynaeve, C; Figueroa, J; Lissowska, J; Hewitt, S; Hooning, MJ; Hollestelle, A; Foekens, R; Koppert, LB; Investigators, K; Bolla, MK; Wang, Q; Jones, ME; Schoemaker, MJ; Keeman, R; Easton, DF; Swerdlow, AJ; Sherman, ME; Schmidt, MK; Pharoah, PD; Garcia-Closas, M (2018-03-01)

  Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ ...
• 

  Radiotherapy in Dupuytren's disease: a systematic review of the evidence 

  Kadhum, M; Smock, E; Khan, A; Fleming, A (2017-09)
• 

  PET/CT with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion 

  Hekman, MCH; Rijpkema, M; Aarntzen, EA; Mulder, SF; Langenhuijsen, JF; Oosterwijk, E; Boerman, OC; Oyen, WJG; Mulders, PFA

  Based on the high expression of Carbonic Anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study ...
• 

  Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. 

  Swerdlow, A
• 

  Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

  Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, B; Gillessen, S; Malik, Z; Jones, R; Parker, C; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, D; Hughes, R; McLaren, D; Lester, J; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND (2018-02-26)

  Background: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in STAMPEDE: a multi-arm multi-stage platform randomised controlled ...
• 

  Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). 

  Mehra, N; Dolling, D; Sumanasuriya, S; Christova, R; Pope, L; Carreira, S; Seed, G; Yuan, W; Goodall, J; Hall, E; Flohr, P; Boysen, G; Bianchini, D; Sartor, O; Eisenberger, MA; Fizazi, K; Oudard, S; Chadjaa, M; Macé, S; de Bono, JS (2018-02-28)

  BACKGROUND: Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE: To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as ...
• 

  Men with a susceptibility to prostate cancer and the role of genetic based screening. 

  Eeles, R; Ni Raghallaigh, H (2018-02)

  Prostate cancer is the second most common malignancy affecting men worldwide, and the commonest affecting men of African descent. Significant diagnostic and therapeutic advances have been made in the past decade. Improvements ...
• 

  Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. 

  Hewitt, LC; Inam, IZ; Saito, Y; Yoshikawa, T; Quaas, A; Hoelscher, A; Bollschweiler, E; Fazzi, GE; Melotte, V; Langley, RE; Nankivell, M; Cunningham, D; Allum, W; Hutchins, GG; Grabsch, HI (2018-05)

  BACKGROUND: Oesophageal (OeC) and gastric (GC) cancer patients are treated with similar multimodal therapy and have poor survival. There remains an urgent clinical need to identify biomarkers to individualise patient ...
• 

  Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. 

  Conti, DV; Wang, K; Sheng, X; Bensen, JT; Hazelett, DJ; Cook, MB; Ingles, SA; Kittles, RA; Strom, SS; Rybicki, BA; Nemesure, B; Isaacs, WB; Stanford, JL; Zheng, W; Sanderson, M; John, EM; Park, JY; Xu, J; Stevens, VL; Berndt, SI; Huff, CD; Wang, Z; Yeboah, ED; Tettey, Y; Biritwum, RB; Adjei, AA; Tay, E; Truelove, A; Niwa, S; Sellers, TA; Yamoah, K; Murphy, AB; Crawford, DC; Gapstur, SM; Bush, WS; Aldrich, MC; Cussenot, O; Petrovics, G; Cullen, J; Neslund-Dudas, C; Stern, MC; Jarai, Z-K; Govindasami, K; Chokkalingam, AP; Hsing, AW; Goodman, PJ; Hoffmann, T; Drake, BF; Hu, JJ; Clark, PE; Van Den Eeden, SK; Blanchet, P; Fowke, JH; Casey, G; Hennis, AJM; Han, Y; Lubwama, A; Thompson, IM; Leach, R; Easton, DF; Schumacher, F; Van den Berg, DJ; Gundell, SM; Stram, A; Wan, P; Xia, L; Pooler, LC; Mohler, JL; Fontham, ETH; Smith, GJ; Taylor, JA; Srivastava, S; Eeles, RA; Carpten, J; Kibel, AS; Multigner, L; Parent, M-E; Menegaux, F; Cancel-Tassin, G; Klein, EA; Brureau, L; Stram, DO; Watya, S; Chanock, SJ; Witte, JS; Blot, WJ; Henderson, BE; Haiman, CA; PRACTICAL/ELLIPSE Consortium (2017-08-01)

  Prostate cancer incidence is 1.6-fold higher in African Americans than in other populations. The risk factors that drive this disparity are unknown and potentially consist of social, environmental, and genetic influences. ...
• 

  Outcome of elderly advanced soft tissue sarcoma patients treated with first line chemotherapy: a pooled analysis of twelve EORTC Soft Tissue and Bone sarcoma Group Trials 

  van der Graaf, W; Jones, R
• 

  Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. 

  Girardi, F; Barnes, DR; Barrowdale, D; Frost, D; Brady, AF; Miller, C; Henderson, A; Donaldson, A; Murray, A; Brewer, C; Pottinger, C; Evans, DG; Eccles, D; EMBRACE; Lalloo, F; Gregory, H; Cook, J; Eason, J; Adlard, J; Barwell, J; Ong, KR; Walker, L; Izatt, L; Side, LE; Kennedy, MJ; Tischkowitz, M; Rogers, MT; Porteous, ME; Morrison, PJ; Eeles, R; Davidson, R; Snape, K; Easton, DF; Antoniou, AC (2018-03-22)

  PurposeBRCA1/BRCA2 predictive test negatives are proven noncarriers of a BRCA1/BRCA2 mutation that is carried by their relatives. The risk of developing breast cancer (BC) or epithelial ovarian cancer (EOC) in these women ...
• 

  Intensity modulated radiotherapy in locally advanced thyroid cancer: Outcomes of a sequential phase I dose-escalation study. 

  Rooney, KP; Miah, AB; Bhide, SA; Guerrero-Urbano, MT; Sharabiani, MT; Newbold, KL; Grove, L; Harrington, KJ; Nutting, CM (2018-03-07)

  BACKGROUND AND PURPOSE: To determine the safety and tolerability of dose-escalation using modestly accelerated IMRT in high-risk locally advanced thyroid cancer requiring post-operative radiotherapy, and to report preliminary ...
• 

  Comparison of six fit algorithms for the intra-voxel incoherent motion model of diffusion-weighted magnetic resonance imaging data of pancreatic cancer patients 

  Gurney-Champion, O; Klaassen, R; Froeling, M; Barbieri, S; Stoker, J; Engelbrecht, MRW; Wilmink, JW; Besselink, MG; van Laarhoven, HWM; Nederveen, AJ
• 

  Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy. 

  Russell, NS; Krul, IM; van Eggermond, AM; Aleman, BMP; Cooke, R; Kuiper, S; Allen, SD; Wallis, MG; Llanas, D; Diallo, I; de Vathaire, F; Smith, SA; Hauptmann, M; Broeks, A; Swerdlow, AJ; Van Leeuwen, FE (2017-12)

  Background: An increased risk of breast cancer following radiotherapy for Hodgkin lymphoma (HL) has now been robustly established. In order to estimate the dose-response relationship more accurately, and to aid clinical ...
• 

  Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. 

  Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; Stuttle, C; Daley, F; Corbishley, CM; Dearnaley, DP; Hall, E; Somaiah, N; CHHiP Trial Investigators (2018-02-03)

  PURPOSE: To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ...

View more